Loviride

Appearance move to sidebar hide Loviride

Clinical data
Other names	R089439; loveride
ATC code	None
Identifiers
IUPAC name 2--2-(2,6-dichlorophenyl)acetamide
CAS Number	147362-57-0 N
PubChem CID	3963
ChemSpider	3826 Y
UNII	3S1R1LZ09H
KEGG	D04786 Y
ChEMBL	ChEMBL37624 Y
CompTox Dashboard (EPA)	DTXSID60869958
Chemical and physical data
Formula	C17H16Cl2N2O2
Molar mass	351.23 g·mol−1
3D model (JSmol)	Interactive image
SMILES Clc1cccc(Cl)c1C(Nc2cc(ccc2C(=O)C)C)C(=O)N
InChI InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23) Y Key:CJPLEFFCVDQQFZ-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Loviride is an experimental antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s, but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to the NNRTIs efavirenz and nevirapine.

References

1. ^ "Loviride". aidsmap.com. Archived from the original on 2007-09-27.
2. ^ Kroon ED, Wit FW, et al. (CAESAR Coordinating Committee) (1997). "Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial". The Lancet. 349 (9063): 1413–1421. doi:10.1016/S0140-6736(97)04441-3. S2CID 20008082.
3. ^ Gatell J, Lange J, Gartland M (1999). "AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group". Antiviral Therapy. 4 (2): 79–86. doi:10.1177/135965359900400204. PMID 10682152. S2CID 22443598.

v t e Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)
Capsid inhibitors	Lenacapavir (LEN)
Entry/fusion inhibitors (Discovery and development)	gp41 (Enfuvirtide (ENF, T-20))◊ CCR5 (Maraviroc (MVC) Vicriviroc†, Cenicriviroc†, Leronlimab†) CD4 (Ibalizumab (IBA), Semzuvolimab§) gp120 (Fostemsavir (FTR))
Integrase inhibitors (Integrase strand transfer inhibitors (INSTI))	Bictegravir (BIC) Cabotegravir (CAB) Dolutegravir (DTG)# Elvitegravir (EVG) Raltegravir (RAL)# BI 224436† MK-2048†
Maturation inhibitors	Bevirimat† BMS-955176§ Fipravirimat§
Protease Inhibitors (PI) (Discovery and development)	1st generation Amprenavir (APV)‡ Fosamprenavir (FPV) Indinavir (IDV)◊ Lopinavir (LPV) Nelfinavir (NFV)◊ Ritonavir (RTV)# Saquinavir (SQV)◊ 2nd generation Atazanavir (ATV)°# Darunavir (DRV)°# Tipranavir (TPV)◊ TMC-310911§
Reverse-transcriptase inhibitors (RTIs)	Nucleoside and nucleotide (NRTI) Nucleoside analogues/NRTIs: Abacavir (ABC)# Didanosine (ddI)◊ Emtricitabine (FTC) Lamivudine (3TC)# Stavudine (d4T)◊ Zalcitabine (ddC)‡ Zidovudine (AZT, ZDV)# Amdoxovir† Apricitabine† Censavudine† Elvucitabine† Islatravir (EFdA, ISL)§ Racivir† Stampidine† Nucleotide analogues/NtRTIs: Tenofovir disoproxil (TDF)# Tenofovir alafenamide (TAF) Non-nucleoside (NNRTI) (Discovery and development) 1st generation Efavirenz (EFV)# Nevirapine (NVP)# Delavirdine (DLV)‡ 2nd generation diarylpyrimidines Dapivirine (DPV) Etravirine (ETR) Rilpivirine (RPV) Doravirine (DOR) Elsulfavirine (ESV)
Combined formulations	Abacavir/lamivudine# Abacavir/dolutegravir/lamivudine° Abacavir/lamivudine/zidovudine Atazanavir/cobicistat Bictegravir/emtricitabine/tenofovir alafenamide° Cabotegravir/rilpivirine Darunavir/cobicistat Darunavir/cobicistat/emtricitabine/tenofovir alafenamide° Dolutegravir/emtricitabine/tenofovir alafenamide Dolutegravir/lamivudine° Dolutegravir/lamivudine/tenofovir alafenamide° Dolutegravir/lamivudine/tenofovir disoproxil°# Dolutegravir/rilpivirine Doravirine/lamivudine/tenofovir disoproxil Efavirenz/emtricitabine/tenofovir disoproxil# Efavirenz/lamivudine/tenofovir disoproxil# Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil Emtricitabine/tenofovir alafenamide Emtricitabine/rilpivirine/tenofovir alafenamide Emtricitabine/rilpivirine/tenofovir disoproxil Emtricitabine/tenofovir disoproxil# Lamivudine/nevirapine/stavudine Lamivudine/nevirapine/zidovudine Lamivudine/raltegravir Lamivudine/tenofovir disoproxil# Lamivudine/zidovudine# Lopinavir/ritonavir#
Pharmacokinetic boosters	Cobicistat (c) Ritonavir (r)#
Experimental agents	Uncoating inhibitors TRIM5alpha (gene) Transcription inhibitors Tat antagonists Translation inhibitors Trichosanthin BNAbs Elipovimab Other Abzyme BIT225† Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Fosdevirine† Griffithsin Hydroxycarbamide KP-1461† Miltefosine Portmanteau inhibitors Scytovirin Seliciclib† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor Failed agents Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir
#WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase III °DHHS recommended initial regimen options. ◊Formerly or rarely used agent.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e